Strategic Rebrand Opportunity to approach Precision for Medicine, Oncology and Rare Disease post-merger synergy. Propose collaborative CRO and REaD (rare disease) service expansions leveraging merged capabilities to target shared pharmaceutical clients seeking end-to-end development across rare diseases and oncology.

Expansion Fit Leverage the expanded global scale and capabilities to pitch integrated trial services to mid-to-large biotechs and pharma companies expanding rare disease and oncology portfolios, emphasizing single-vendor convenience and accelerated timelines.

Technology Leverage Position as a tech-enabled CRO using tools like SAS and WordPress within an agile digital engagement strategy. Highlight data analytics, streamlined study management, and scalable tech stack as differentiators for complex oncology/rare disease trials.

Financial Signals Revenue in the low-to-mid seven-figure range signals growth potential and room for upsell into larger, multi-study programs. Prioritize discussions around expanded trial scopes, late-phase support, and transitioning ongoing studies to Precision for Medicine, Oncology and Rare Disease platforms.

Competitive Positioning Benchmark against peers with similar scale to pursue larger CDMO and CRO collaborations. Emphasize unique combined capabilities not offered by traditional CROs, and target clients seeking integrated oncology and rare disease solutions across global sites.